Great Tree Pharmacy Co., Ltd.
TPEX:6469 Rapport sur les actions
Capitalisation boursière : NT$23.3b
Ajouter à la liste de surveillanceGreat Tree Pharmacy Croissance future
Future contrôle des critères 2/6 Great Tree Pharmacy devrait augmenter ses bénéfices et son chiffre d'affaires de 15.4% et de 12.8% par an respectivement. Le BPA devrait croître de de 12.1% par an. Le rendement des capitaux propres devrait être 20.8% dans 3 ans.
Informations clés
15.4%
Taux de croissance des bénéfices
12.1%
Taux de croissance du BPA
Consumer Retailing croissance des bénéfices 19.2% Taux de croissance des recettes 12.8% Rendement futur des capitaux propres 20.8% Couverture par les analystes Low
Dernière mise à jour 11 Nov 2024
Mises à jour récentes de la croissance future
Consensus EPS estimates fall by 13% May 14
Consensus EPS estimates fall by 18% Aug 11
Price target increased by 7.6% to NT$324 Feb 24
Consensus forecasts updated Aug 30
Afficher toutes les mises à jour
Third quarter 2024 earnings released: EPS: NT$1.27 (vs NT$1.26 in 3Q 2023) Nov 11
New minor risk - Shareholder dilution Aug 21
Second quarter 2024 earnings released: EPS: NT$1.29 (vs NT$1.29 in 2Q 2023) Aug 13
Great Tree Pharmacy Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024 Aug 02
Upcoming dividend of NT$3.60 per share Jul 03
Dividend of NT$3.60 announced Jun 13
Great Tree Pharmacy Co., Ltd. Announces Cash Dividend , Payable on July 31, 2024 Jun 13
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 18
Consensus EPS estimates fall by 13% May 14 Great Tree Pharmacy Co., Ltd. to Report Q1, 2024 Results on May 10, 2024 May 03
Less than half of directors are independent Apr 03
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 06 Great Tree Pharmacy Co., Ltd. announced a financing transaction
New minor risk - Shareholder dilution Dec 23
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 15
New major risk - Earnings quality Aug 12
Great Tree Pharmacy Co., Ltd. Announces Convener of Audit Committee Changes Aug 11
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 11
Consensus EPS estimates fall by 18% Aug 11
Upcoming dividend of NT$4.70 per share at 1.3% yield Jun 28
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Jun 07
Great Tree Pharmacy Co., Ltd. Announces Cash Dividend for the Year 2022, Payable on July 28, 2023 Jun 06
Great Tree Pharmacy Co., Ltd. Appoints Min-Hsiung Pan as Member of the Audit Committee and the Remuneration Committee Jun 02
Great Tree Pharmacy Co., Ltd. Elects Min-Hsiung Pan as Independent Director Jun 01
Now 23% undervalued May 12
Full year 2022 earnings: EPS misses analyst expectations Mar 01
Price target increased by 7.6% to NT$324 Feb 24
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Less than half of directors are independent Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 13
Now 20% undervalued Oct 26 Great Tree Pharmacy Co., Ltd. announced that it has received TWD 220 million in funding from Sugi Holdings Co.,Ltd. Sep 17
Great Tree Pharmacy Co., Ltd. announced that it expects to receive funding from Sugi Holdings Co.,Ltd. Sep 08
Consensus forecasts updated Aug 30
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 13
Investor sentiment improved over the past week Jul 11
Upcoming dividend of NT$2.57 per share Jun 22
Great Tree Pharmacy Co., Ltd. Announces Cash Dividend, Payable on July 21, 2022 Jun 15
Investor sentiment improved over the past week Jun 10
Less than half of directors are independent May 16
First quarter 2022 earnings released: EPS: NT$1.67 (vs NT$1.04 in 1Q 2021) May 14
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 28
Great Tree Pharmacy Co., Ltd. Approves Dividend Distribution for the Year Ended December 31, 2021 Feb 27
Great Tree Pharmacy Co., Ltd., Annual General Meeting, May 31, 2022 Feb 26
Investor sentiment improved over the past week Feb 24
Third quarter 2021 earnings released: EPS NT$1.51 (vs NT$0.66 in 3Q 2020) Nov 12
Investor sentiment deteriorated over the past week Sep 10
Investor sentiment improved over the past week Aug 24
Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$0.86 in 2Q 2020) Aug 13
Investor sentiment improved over the past week Jul 23
Upcoming dividend of NT$0.99 per share Jul 15
Investor sentiment improved over the past week Jun 24
First quarter 2021 earnings released: EPS NT$1.34 (vs NT$0.92 in 1Q 2020) May 15
Investor sentiment improved over the past week Mar 24
There Are Reasons To Feel Uneasy About Great Tree Pharmacy's (GTSM:6469) Returns On Capital Mar 24
Great Tree Pharmacy Co., Ltd. Approves Dividend Distribution Mar 20
Great Tree Pharmacy Co., Ltd., Annual General Meeting, Jun 24, 2021 Mar 19
Full year 2020 earnings released: EPS NT$3.73 (vs NT$2.77 in FY 2019) Mar 19
New 90-day high: NT$101 Mar 12
Is Great Tree Pharmacy (GTSM:6469) A Risky Investment? Mar 03
Is Great Tree Pharmacy Co., Ltd.'s (GTSM:6469) Stock's Recent Performance A Reflection Of Its Financial Health? Feb 09
Great Tree Pharmacy's (GTSM:6469) Earnings Are Growing But Is There More To The Story? Jan 19
Did You Miss Great Tree Pharmacy's (GTSM:6469) 71% Share Price Gain? Dec 28
Should We Be Excited About The Trends Of Returns At Great Tree Pharmacy (GTSM:6469)? Dec 09
New 90-day high: NT$100.00 Nov 24
Third quarter 2020 earnings released: EPS NT$0.86 Nov 12
New 90-day high - NT$94.50 Aug 24
First half earnings released Aug 13
Prévisions de croissance des bénéfices et des revenus TPEX:6469 - Estimations futures des analystes et données financières antérieures (TWD Millions ) Date Recettes Les revenus Flux de trésorerie disponible Cash from Op Moy. Nombre d'analystes 12/31/2026 22,439 963 1,049 1,249 3 12/31/2025 20,119 826 763 1,123 3 12/31/2024 17,354 713 -536 1,020 1 9/30/2024 16,974 685 571 973 N/A 6/30/2024 16,690 681 998 1,378 N/A 3/31/2024 16,536 678 1,019 1,374 N/A 12/31/2023 16,144 666 564 890 N/A 9/30/2023 15,735 655 649 971 N/A 6/30/2023 15,294 661 108 433 N/A 3/31/2023 15,185 739 535 830 N/A 12/31/2022 14,565 700 911 1,227 N/A 9/30/2022 13,827 644 889 1,146 N/A 6/30/2022 13,124 580 1,164 1,441 N/A 3/31/2022 11,993 454 688 964 N/A 12/31/2021 11,281 407 823 1,078 N/A 9/30/2021 10,617 354 819 1,091 N/A 6/30/2021 9,954 295 820 1,042 N/A 3/31/2021 9,108 220 494 736 N/A 12/31/2020 8,641 194 477 728 N/A 9/30/2020 8,079 171 126 420 N/A 6/30/2020 7,540 163 -88 214 N/A 3/31/2020 7,137 156 -57 246 N/A 12/31/2019 6,602 136 -54 225 N/A 9/30/2019 6,170 134 108 341 N/A 6/30/2019 5,727 124 -2 246 N/A 3/31/2019 5,296 109 68 277 N/A 12/31/2018 4,901 106 -51 131 N/A 9/30/2018 4,503 104 17 180 N/A 6/30/2018 4,173 107 N/A 252 N/A 3/31/2018 3,889 107 N/A 147 N/A 12/31/2017 3,624 102 N/A 157 N/A 9/30/2017 3,420 96 N/A 62 N/A 6/30/2017 3,192 92 N/A 127 N/A 3/31/2017 2,983 90 N/A 64 N/A 12/31/2016 2,802 93 N/A 129 N/A 9/30/2016 2,615 101 N/A 107 N/A 6/30/2016 2,465 94 N/A 25 N/A 3/31/2016 2,317 91 N/A 76 N/A 12/31/2015 2,160 77 N/A -3 N/A 9/30/2015 2,047 83 N/A 11 N/A 6/30/2015 1,919 79 N/A -14 N/A 3/31/2015 1,774 82 N/A -17 N/A 12/31/2014 1,662 96 N/A 95 N/A 9/30/2014 1,473 75 N/A 55 N/A 6/30/2014 1,349 80 N/A 74 N/A 3/31/2014 1,242 74 N/A 64 N/A 12/31/2013 1,136 68 N/A 55 N/A
Afficher plus
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 6469 ( 15.4% par an) est supérieure au taux d'épargne ( 1.1% ).
Bénéfices vs marché: Les bénéfices de 6469 ( 15.4% par an) devraient croître plus lentement que le marché TW ( 20.2% par an).
Croissance élevée des bénéfices: Les bénéfices de 6469 devraient augmenter, mais pas de manière significative .
Chiffre d'affaires vs marché: Le chiffre d'affaires de 6469 ( 12.8% par an) devrait croître plus lentement que le marché de TW ( 12.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 6469 ( 12.8% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 6469 devrait être élevé dans 3 ans ( 20.8 %)
Découvrir les entreprises en croissance Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}